Cis-platinum chemotherapy for ocular basal cell carcinoma

Michael Morley, Paul T Finger, Martin Perlin, Lora R Weiselberg, Daniel S DeBlasio

Abstract
We have used intravenous cis-platinum chemotherapy in the treatment of three patients with basal cell carcinoma of the lid extending into the orbit. Cis-platinum chemotherapy caused a reduction in tumour size and thereby delayed surgery in all cases. It allowed for local resection in one case, appeared to delay a patient's exenteration in a second case, and was used prior to radiotherapy in a third case. While not curative, cis-platinum may be useful as an adjuvant to decrease tumour mass prior to local excision and for patients who refuse or must delay exenteration.

Basal cell carcinoma is the commonest malignant tumour of the eyelids.1 Surgical excision is the treatment of choice because of the high rate of cure and excellent cosmetic and functional results.2-4 However, there are circumstances when surgical resection is impossible or when a patient refuses to have surgery. Other forms of treatment have been described including radiotherapy, chemotherapy, phototherapy, drug therapy, immunotherapy, and cryotherapy.5-24 Radiotherapy has been successful in the treatment of basal cell carcinoma, but associated lash loss, dry eye, keratopathy, cataract, retinopathy, and optic neuropathy have been reported.13-16 While cryotherapy has been used for small superficial tumours, newer methods including immunotherapy, phototherapy, and drug therapy are still being investigated.20-22

Materials and methods
Three patients with biopsy proved basal cell carcinoma and who refused exenteration were offered chemotherapy as a possible alternative to surgery. Our treatment protocol was a variation of that described by Luxenberg and Guthrie.17,18 The patients were admitted to hospital and followed up by an ophthalmologist and medical oncologist. On admission the height and weight were measured to calculate body surface area (BSA). Routine admission laboratory studies included creatinine clearance, sequential multiple analyser profile-20, prothrombin time, activated partial thromboplastin time, electrocardiogram, chest x ray, complete blood count, and urine analysis. Patients were hydrated with normal saline, 125 ml/h, overnight prior to chemotherapy. On the day of chemotherapy, 20% mannitol (100 ml) was administered intravenously, followed immediately by cis-platinum (75-85 mg/square metre BSA) run in over two hours. Vigorous hydration was continued for 24 hours. Dexamethasone phosphate 10 mg, metoclopramide 50 mg, diphenhydramine hydrochloride 50 mg, perchlorperazine edisylate 10 mg, and droperidol 5 mg were used to reduce the side effects of the cis-platinum. Fluid balance, electrolytes, and renal function were monitored after administration of chemotherapy. Patients were discharged within 48 hours after chemotherapy.

Figure 1B
Chemotherapy of basal cell carcinoma has also been tried as treatment for tumours involving the orbit and adnexa.17-18 A total of eight cases of chemotherapy as a primary treatment for basal cell carcinoma in the eyelids have been reported.17-18 We describe our experience in treating three cases of basal cell carcinoma involving the orbit and eyelids with intravenous cis-platinum.

Figure 1A
(A) A pretreatment external photograph of the nodular basal cell carcinoma on the right lower lid (15 August 1985). Note the tumour-associated lateral ecropion. (B) A post-treatment external photograph of the nodular basal cell carcinoma on the right lower lid two months after the onset of intravenous cis-platinum chemotherapy (15 October 1985). Note the marked reduction in size of the superficial tumour and partial resolution of the lateral ecropion.
Figure 2A Pretreatment computed tomography of the orbit showing tumour invasion into the inferior and inferotemporal orbit (arrows). (B) Post-treatment computed tomography of the orbit showing a reduction in tumour volume (arrows).

Case reports

CASE 1
An 80-year-old white male presented in May 1985 with a two-year history of a right lower lid mass (Figs 1A). Ophthalmic examination revealed 20/40 vision in the right eye and full ocular motility. Slit-lamp biomicroscopy revealed a lateral ectropion and an extensive nodular tumour in the right lower lid. Computed tomography of the orbit demonstrated a mass on the right lower lid, extending into the inferior orbit to the level of the inferior rectus (Figs 2A). An incisional biopsy revealed basal cell carcinoma. Our patient refused surgical resection and was offered the alternative of cis-platinum chemotherapy.

Cis-platinum was administered without complication in July 1985. Two weeks later the tumour had regressed in size by approximately 30% (Fig 1B). A second course of cis-platinum was given in August 1985, and two weeks later the tumour was reduced in size by approximately 40%. We noted that the patient suffered mild, transient mental confusion associated with the chemotherapy and antiemetic therapy. Repeat computed tomography of the orbit confirmed a reduction in the size of the tumour (Fig 2B), and a third course of cis-platinum was administered in October 1985. Again treatment was complicated by transient night time mental confusion, this time requiring treatment with haloperidol. Because of the difficulty with therapy and the reduction in the size of the tumour and its intraorbital extent, this patient elected to proceed with local surgical excision in November 1985. An anterior orbitotomy and tumour excision with frozen section control provided negative margins. Then a modified semicircular flap with skin grafting was performed. Postoperative examinations showed no loss of vision and normal ocular motility. Permanent margins were negative for carcinoma. Follow-up reports four years later showed no evidence of recurrence.

CASE 2
A 66-year-old white female presented in August 1985 with a five-year history of a mass on the right lower lid. Ophthalmic examination showed a visual acuity of 20/20 in the right eye with restriction of infraduction. A large mass extended from the medial canthus across the entire lower lid to 5 mm beyond the lateral canthus (Fig 3). An incisional biopsy revealed basal cell carcinoma. Computed tomography of the orbit showed tumour invading the orbit, displacing the globe superiorly, and contiguous with the inferior rectus muscle. Surgical resection was refused. Cis-platinum chemotherapy was offered, and the patient received a course of intravenous cis-platinum in September and a second in November 1985. While partial regression was noted on clinical and repeat CT examinations, there was still obvious lid, conjunctival, and residual orbital involvement. Again surgical resection was recommended, and again the patient refused. In August 1986 she returned with pain and agreed to undergo exenteration.

CASE 3
A 68-year-old white male presented in December 1983 with a right lower lid mass present for one year. The lesion was noted to involve a 33 mm of the lower lid, and was diagnosed as an infiltrating morpheaform basal cell carcinoma by incisional biopsy. Sinus x rays and CT appearances of the orbit and sinuses were normal. He was treated with electron beam (external) radiation therapy.
and was irradiated with 5977 cGy in 30 fractions over 44 days in March 1984. The tumour appeared to respond well to the treatment, with complete regression of the visible part. Post irradiation epiphora and cicatrix formation with entropion were noted.

In May 1987, after three years of local control, the patient returned with recurrent basal cell carcinoma of the right lower lid and a mucoid discharge from the medial canthal area. The visual acuity in the right eye was 20/40 and he had full ocular motility. Computed tomography of the orbit revealed an abnormal soft tissue density anterior and medial to the globe with slight postseptal extension (Fig 4A). The ethmoidal and frontal sinuses showed mucosal thickening and bony erosion, with no evidence of tumour extension. An incisional biopsy was positive for basal cell carcinoma. Surgical resection was recommended, but since the tumour appeared to be localised to the nasal orbit a presurgical trial of cis-platinum chemotherapy was offered. The patient underwent three courses of chemotherapy in August 1987, September 1987, and November 1987 with reduction in the apparent size of the mass (Fig 4B). Since he developed severe akathisia after receiving metoclopramide with his first cycle of treatment, lorazepam was subsequently used as an antiemetic agent. The patient did not return for follow-up until June 1988, and a repeat biopsy again revealed basal cell carcinoma. Two additional cycles of chemotherapy were administered in July and September 1988. Then in December the patient was noted to have a rise in his creatinine level to 168 μmol/l and a reduction in his creatinine clearance to 46 ml/min. This precluded further chemotherapy.

We undertook extensive lid, orbit, and sinus resection in an attempt to excise the tumour. Multiple frozen sections were positive for tumour, and I-125 brachytherapy implants were placed in the frontal sinus and against the remaining ethmoidal sinuses as a 30 Gy boost to external radiotherapy. Then 60 Gy of external beam radiation was delivered to the orbit and sinuses. Eighteen months after radiotherapy there has been no evidence of new tumour growth.

Discussion
This is the second series of cases recording a reduction in the size of basal cell carcinomas of the lids and orbit associated with cis-platinum chemotherapy. All three patients we treated were considered to have partial regression of their tumour. In one of the three cases partial regression allowed for local excision with negative margins, in another delayed exenteration, and in the third it postponed radiotherapy.

There are significant side effects associated with intravenous cis-platinum chemotherapy.22-25 As seen in case 3 in our report, dose related and cumulative renal insufficiency is the major toxic effect.26 Thus pre-existing renal insufficiency is a contraindication to its use. Careful attention to fluid status, creatinine clearance, and creatinine levels is mandatory.

Severe nausea and vomiting are frequently observed after the administration of cis-platinum, so that administration of antiemetics is standard practice. Two of our patients (cases 1 and 3) had neurological reactions to the combination of medicines used in this protocol. These reactions were probably due to the antiemetic therapy, not the cis-platinum. Ototoxicity has been observed in some patients, usually manifested by tinnitus or high frequency hearing loss.27

There are a number of reports describing the ocular side effects of cis-platinum or chemotherapeutic regimens that contain cis-platinum: cortical blindness, optic disc swelling, retrobulbar neuritis, homonymous hemianopsia, retinal pigmentary changes, abnormalities of electroretinogram and visually evoked potentials and encephalopathy.28-31

While the preferred method of treatment of basal cell carcinoma is surgical excision, there are circumstances when that is impossible. Occasionally a patient refuses to have surgery. In cases where extensive surgery is refused, less extensive surgery coupled with an alternative treatment may be effective.

All three patients reported on here, including one who was pretreated with radiation therapy, had an objective response to treatment. No case attained complete remission, and all required
further treatment. Our data confirm the observations of Luxenberg and Guthrie that lid and periorcular basal cell carcinoma will respond to intravenous cis-platinum with adriamycin.17 18 In their cases the commonest outcome was a partial reduction in tumour size requiring additional treatment to control tumour spread. Our experience was similar in that cis-platinum alone was not curative, yet it served as a helpful adjunct in the management of basal cell carcinoma of the eyelids and orbit.

The authors have no proprietary interest in the chemotherapeutic agent cis-platinum.

We thank Dr Frederick A Jakobiec, for his original suggestion to contact Dr Luxenberg, and Dr Jason Slakter, Dr Peter Small, Dr Jay I. Bosworth, and Dr Samuel Packer for sharing in the care of these patients.